Cargando…
Efficacy and safety of an inactivated virus-particle vaccine for SARS-CoV-2, BIV1-CovIran: randomised, placebo controlled, double blind, multicentre, phase 3 clinical trial
OBJECTIVE: To report the efficacy, safety, and exploratory immunogenicity findings of two 5 µg doses of the BIV1-CovIran vaccine. DESIGN: Randomised, placebo controlled, double blind, multicentre, phase 3 clinical trial. SETTING: In six cities of Iran, including Bushehr, Isfahan, Karaj, Mashhad, Shi...
Autores principales: | Mohraz, Minoo, Vahdat, Katayoun, Ghamari, Seyyed-Hadi, Abbasi-Kangevari, Mohsen, Ghasemi, Erfan, Ghabdian, Yasaman, Rezaei, Negar, Pouya, Maryam Amini, Abdoli, Asghar, Malekpour, Mohammad-Reza, Koohgir, Keyvan, Saeedi Moghaddam, Sahar, Tabarsi, Payam, Moghadami, Mohsen, Khorvash, Farzin, Khodashahi, Rozita, Salehi, Mohammadreza, Hosseini, Hamed |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group Ltd.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520577/ https://www.ncbi.nlm.nih.gov/pubmed/37734752 http://dx.doi.org/10.1136/bmj-2023-070464 |
Ejemplares similares
-
Safety and immunogenicity of an inactivated virus particle vaccine for SARS-CoV-2, BIV1-CovIran: findings from double-blind, randomised, placebo-controlled, phase I and II clinical trials among healthy adults
por: Mohraz, Minoo, et al.
Publicado: (2022) -
Assessment of BIV1-CovIran inactivated vaccine–elicited neutralizing antibody against the emerging SARS-CoV-2 variants of concern
por: Salehi, Mohammadreza, et al.
Publicado: (2022) -
The protection quest is a primary key to sharing the neutralizing antibody response to cover against all emerging VOCs based on BIV1-CovIran studies
por: Shafaati, Maryam, et al.
Publicado: (2023) -
Efficacy and safety of an inactivated virus-particle vaccine for SARS-CoV-2, BIV1-CovIran: randomised, placebo controlled, double blind, multicentre, phase 3 clinical trial
Publicado: (2023) -
Correction: Safety and immunogenicity of an inactivated virus particle vaccine for SARS-CoV-2, BIV1-CovIran: findings from double-blind, randomised, placebo-controlled, phase I and II clinical trials among healthy adults
Publicado: (2022)